Cometriq: new protein kinase inhibitor for thyroid carcinoma

Cometriq (cabozantinib) is indicated for the treatment of adults with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.

Medullary thyroid cancer is a rare malignancy originating from calcitonin-producing parafollicular C cells of the thyroid. SCIENCE PHOTO LIBRARY
Medullary thyroid cancer is a rare malignancy originating from calcitonin-producing parafollicular C cells of the thyroid. SCIENCE PHOTO LIBRARY

Cabozantinib inhibits the activity of tyrosine kinases (including RET, MET and VEGF receptors) involved in cellular function and pathologic processes such as oncogenesis, metastasis, tumour angiogenesis and maintenance of the tumour microenvironment.

Survival benefit

The safety and efficacy of cabozantinib were established in a randomised, double-blind trial involving 330 patients with unresectable locally advanced or metastatic medullary thyroid cancer who had radiographic evidence of disease progression within 14 months before study entry.

Patients who received cabozantinib 140mg once daily survived for a median of 11.2 months without tumour progression compared with a median of 4 months in the placebo group (HR 0.28, 95% CI 0.19-0.40, p<0.001). Prior therapy with tyrosine kinase inhibitors had no influence on progression-free survival rates.

The overall response rate in cabozantinib-treated patients was 28%, compared with 0% in those who received placebo (p<0.0001). Estimated responses lasted a median of 14.6 months in the cabozantinib arm (95% CI 11.1-17.5 months).

Safety

The most commonly reported serious adverse reactions of cabozantinib were pneumonia, mucosal inflammation, hypocalcaemia, dysphagia, dehydration, pulmonary embolism and hypertension.

View Cometriq drug record

Further information: Swedish Orphan Biovitrum

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more